News | June 17, 2008

NeoMend Receives FDA Panel’s Recommendation for Approval of ProGEL Surgical Sealant

June 18, 2008 - NeoMend Inc. today said its ProGEL Surgical Sealant received a recommendation for approval from the FDA’s Anesthesiology and Respiratory Therapy Devices Advisory Panel.

The panel’s recommendation will be considered by the FDA during completion of its review of the premarket approval for ProGEL. The panel’s recommendation for FDA approval was conditioned principally on NeoMend conducting a post approval study to gather more safety data.

The panel’s decision was based on the results of a multi-center, prospective, randomized clinical trial, which demonstrated ProGEL’s success in sealing intra-operative air leaks after lung resection surgery. NeoMend estimates more than 100,000 lung resection surgeries are performed annually in the U.S., with lung cancer comprising the majority of cases.

Post-surgical air leaks represent the most common complication following lung surgery. These air leaks can lead to serious complications prolonged hospitalizations, and increased costs as a direct result of the continuous contamination of the chest cavity. To date, surgical options to control or reduce these air leaks have been limited.

During the ProGEL clinical trial 161 patients were enrolled at five of the leading lung cancer treatment centers in the U.S. At the end of surgery in which a portion of the lung is removed, the surgeon would use standard techniques, suturing or stapling, to seal any air leaks that were present. Patients were then randomized to either a control group, who received no further treatment, or they were randomized to the treatment group for application of ProGEL to the air leaks. In this study, ProGEL was not used prophylactically to prevent air leaks.

As presented to the panel, 35 percent of the 103 ProGEL treated patients were free of air leaks through one month follow up compared to only 14 percent of the 58 patients randomized to the control group. Also presented to the panel was the benefit of using ProGEL to keep patients free of air leaks, as the trial demonstrated that the mean average of hospital stay was nearly two days shorter for the ProGEL patients.

“Lung cancer is the leading cause of cancer deaths of both men and women in the U.S. Improved surgical tools and techniques to successfully treat these patients will significantly reduce perioperative morbidity and mortality,” said Garrett Walsh, M.D., professor of surgery at the University of Texas, MD Anderson Cancer Center and a study investigator. “The results of this trial clearly show the benefit to our patients offered by this product.”

For more information:

Overlay Init